奥希替尼治疗晚期非小细胞肺癌的临床研究进展

Clinical research progress of osimertinib in treatment of advanced non-small cell lung cancer

奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),与第一代、第二代EGFR-TKI相比,奥希替尼对表皮生长因子受体致敏突变阳性(EGFR+)T790M基因突变有更好的抑制作用,且对中枢神经系统亦有良好的疗效。多项临床研究证实奥希替尼对接受一代、二代EGFR-TKI治疗后进展或耐药的EGFR+及转移性非小细胞肺癌患者具有较好的疗效和安全性。

Osimertinib is the third-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI).Compared with the first and second generation EGFR-TKI,osimertinib has the better inhibitory effect on EGFR sensitized mutation positive(EGFR+)T790M gene mutation,and also has a good curative effect on the central nervous system.Several clinical trials have shown that osimertinib has good anti-tumor effects and safety in the treatment of EGFR+and metastatic non-small cell lung cancer who have progressed or resisted after receiving the treatment of the first and second generation EGFR-TKI.